MBX Biosciences
Manufacturing · Indiana, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11711 N Meridian St Ste 300, Carmel, Ind...Phone Number
(317) 659-0200Website
www.mbxbio.comRevenue
-Stock Symbol
MBXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About MBX Biosciences
MBX Biosciences was founded in 2018, it is a biotechnology company creating therapies for rare endocrine diseases. Members of MBX's leadership team previously collaborated in the creation of highly successful endocrine drugs (Humalog®, Forteo®) and three Indiana-based companies (Marcadia, Calibrium and MB2). MBX is strengthened by world-class proprietary technology and drug candidates licensed from the DiMarchi Indiana University laboratory. The company is supported by investment from leading life science investors that include Frazier Healthcare Partners, OrbiMed, and New Enterprise Associates.Explore more
MBX Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MBX Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on MBX Biosciences recently announced quarterly report
Funding: Get notified immidiatlly once MBX Biosciences has new funding data
Congratulate Masked Content for being promoted to Masked Content at MBX Biosciences
Check if MBX Biosciences has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when MBX Biosciences launches new products
Click to see if MBX Biosciences had a recent Job posting/layoffs
Check out if MBX Biosciences is spiking on competitors!
MBX Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at MBX Biosciences
Find 3 more new buyers
Compare Similar Companies to MBX Biosciences
Compare insights from companies similar to MBX Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MBX Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MBX Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MBX Biosciences.
MBX Biosciences financials insights
Gather financial insights about MBX Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$34.6M
2022
Series B
$115M
2024
Series C
$63.5M
MBX Biosciences Tech Stack
A closer look at the technologies used by MBX Biosciences
See more technologies
Most Recent Scoops
Project
reported that the B1 cohort of its MBX 2109 Multiple Ascending Dose study demonstrated a smooth pharmacokinetic rise maintained through repeated administration and dose escalation to 120 mg, with markedly improved gastrointestinal tolerability compared to the single 180 mg dose with only one transient event of loose stool and no nausea or vomiting observed.
Pharmaceuticals, Clinical Operations
Project
MBX Biosciences has included urine calcium normalization as a key secondary endpoint in the Phase 3 study for Canvu Paratide (Aveil), a measure not present in the once-daily PTH replacement therapy label and considered potentially transformative for product differentiation.
Pharmaceuticals
Project
reported a 94% opt-in rate among patients completing Phase 2 of the Aveil study who chose to continue into the open-label extension, with excellent safety and tolerability observed throughout.
Clinical Operations
Project
demonstrated proof of concept for its once-weekly PTH replacement therapy pro drug, Canvu Paratide (Aveil), in a Phase 2 study, achieving a 63% responder rate at 12 weeks meeting the primary endpoint with statistical significance which improved to 79% at six months in the open label extension (OLE).
Migration, Integration
Project
Pharmaceuticals, Clinical Operations
MBX Biosciences News & Media
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an investor webcast and conference call at 8:00 am ET on Friday, June 12, 2026 to discuss presentations for once-weekly canvuparatide at the upcoming Endocrine Society’s Annual MeetingChief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider sale after a year of rapid stock gains.MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
CARMEL, Ind. and BURLINGTON, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at the Jefferies 2026 Global Healthcare Conference in New York CMBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo)
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MBX Biosciences
Sign Up For FreeTo access detailed company insights
MBX Biosciences was founded in 2018, it is a biotechnology company creating therapies for rare endocrine diseases. Members of MBX's leadership team previously collaborated in the creation of highly successful endocrine drugs (Humalog®, Forteo®) and three Indiana-based companies (Marcadia, Calibrium and MB2). MBX is strengthened by world-class propr... Read More
